AN2 Therapeutics, Inc.
ANTX
$1.25
-$0.04-3.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.86% | -6.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.88% | -25.88% | |||
| Operating Income | 26.88% | 25.88% | |||
| Income Before Tax | 40.99% | 11.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 40.99% | 11.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 40.99% | 11.69% | |||
| EBIT | 26.88% | 25.88% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 41.08% | 11.74% | |||
| Normalized Basic EPS | 28.41% | 27.27% | |||
| EPS Diluted | 41.08% | 11.74% | |||
| Normalized Diluted EPS | 28.41% | 27.27% | |||
| Average Basic Shares Outstanding | 0.14% | 0.06% | |||
| Average Diluted Shares Outstanding | 0.14% | 0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||